MedPath

Bridge Device for Surgical Pain for Rotator Cuff Surgery

Not Applicable
Completed
Conditions
Pain
Rotator Cuff Injuries
Interventions
Device: Bridge Percutaneous Nerve Field Stimulator
Registration Number
NCT06071884
Lead Sponsor
Steven Orebaugh
Brief Summary

The objective of the trial is to investigate the efficacy of the Bridge device in reducing post-operative pain and post-operative opioid consumption in patients undergoing rotator cuff surgery with the typical mode of anesthesia, nerve block plus propofol sedation.

Detailed Description

The interscalene block is the gold standard for postoperative pain management following rotator cuff surgery. However, the duration of the block does not cover rehabilitation. Therefore, in most cases, patients are discharged from the surgical center with an opioid prescription. There is a growing need to investigate complementary, non-pharmacologic pain-management methods. The Bridge device, which provides auricular neuromodulation of various cutaneous nerves near the ear, is manufactured by Masimo and previously FDA-approved to reduce symptoms of opioid withdrawal. It is a promising technology that could help relieve post-operative pain without exposing patients to the adverse effects of opioids or other pain-relieving medications. The objective of the trial is to investigate the efficacy of the Bridge device in reducing post-operative pain and post-operative opioid consumption in patients undergoing rotator cuff surgery with the typical mode of anesthesia, nerve block plus propofol sedation. Those enrolled will be assigned to a study group and compared to historic cohort (control group). Historic control group involves patients that underwent same surgical procedure performed at the surgical center involved in the study, by the same surgical operator, between 2020 and 2023.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
15
Inclusion Criteria
  • Greater than 18 years of age
  • Willing and able to provide informed consent
  • Scheduled to undergo elective rotator cuff surgery at UPMC
  • No pre-existing medical conditions which would prevent application of the Bridge device on auricle of ear (i.e., skin infection, rash)
Exclusion Criteria
  • Opioids dependence
  • Chronic pain condition with daily opioid use
  • Anatomical malformation, which may interfere with placement of the nerve block
  • Raynaud's disease diagnosis
  • Vasculopathy
  • Hemophilia or other coagulopathy, or use of active anticoagulation other than aspirin
  • Patient refusal
  • Pacemaker
  • Pre-existing medical conditions which would prevent application of the Bridge device on auricle of ear (i.e., skin infection, rash)
  • Psoriasis vulgaris

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Bridge Percutaneous Nerve Field StimulatorBridge Percutaneous Nerve Field StimulatorThe case group (n = 15) will receive an activated Bridge device after surgery and continuing wearing the device until post-operative day (POD) 7.
Primary Outcome Measures
NameTimeMethod
Oral Opioid Use POD 4Post-Operative Day 4

This outcome will be measured by total Oral Morphine Equivalents (OME, mg) abstracted from the medical records.

Oral Opioid Use POD 1Post-Operative Day 1

This outcome will be measured by total Oral Morphine Equivalents (OME, mg) abstracted from the medical records.

Oral Opioid Use POD 2Post-Operative Day 2

This outcome will be measured by total Oral Morphine Equivalents (OME, mg) abstracted from the medical records.

Oral Opioid Use POD 5Post-Operative Day 5

This outcome will be measured by total Oral Morphine Equivalents (OME, mg) abstracted from the medical records.

Oral Opioid Use POD 3Post-Operative Day 3

This outcome will be measured by total Oral Morphine Equivalents (OME, mg) abstracted from the medical records.

Secondary Outcome Measures
NameTimeMethod
Self-Reported Pain Scores POD 1Post-Operative Day 1

Pain scores will be completed on a Numeric Rating Scale (NRS) of 0=no pain at all and 10=the most severe pain.

Self-Reported Pain Scores POD 4Post-Operative Day 4

Pain scores will be completed on a Numeric Rating Scale (NRS) of 0=no pain at all and 10=the most severe pain.

Self-Reported Pain Scores POD 2Post-Operative Day 2

Pain scores will be completed on a Numeric Rating Scale (NRS) of 0=no pain at all and 10=the most severe pain.

Local adverse events on ear related to device POD 1Post-operative Day 1

Recorded as yes/no for adverse events related to the device such as pain or skin irritation

Self-Reported Pain Scores POD 3Post-Operative Day 3

Pain scores will be completed on a Numeric Rating Scale (NRS) of 0=no pain at all and 10=the most severe pain.

Self-Reported Oral Opioid Use POD 7Post-Operative Day 7

Collected through the subject diary and recorded as total dosage (mg) taken

Self-Reported Pain Scores POD 6Post-Operative Day 6

Averaged NRS pain scores (0=no pain at all and 10=the most severe pain) collected via subject diary after hospital discharge every 8-hours

Self-Reported Pain Scores POD 5Post-Operative Day 5

Averaged NRS pain scores (0=no pain at all and 10=the most severe pain) collected via subject diary after hospital discharge every 8-hours

Self-Reported Oral Opioid Use POD 6Post-Operative Day 6

Collected through the subject diary and recorded as total dosage (mg) taken

Self-Reported Pain Scores POD 7Post-Operative Day 7

Averaged NRS pain scores (0=no pain at all and 10=the most severe pain) collected via subject diary after hospital discharge every 8-hours

Adverse events related to opioid POD 7Post-Operative Day 7

Recorded as yes/no for adverse events related to opioids like nausea, vomiting, dizziness, and itching

Local adverse events on ear related to device POD 2Post-operative Day 2

Recorded as yes/no for adverse events related to the device such as pain or skin irritation

Local adverse events on ear related to device POD 3Post-operative Day 3

Recorded as yes/no for adverse events related to the device such as pain or skin irritation

Local adverse events on ear related to device POD 5Post-operative Day 5

Recorded as yes/no for adverse events related to the device such as pain or skin irritation

Adverse events related to opioid POD 5Post-Operative Day 5

Recorded as yes/no for adverse events related to opioids like nausea, vomiting, dizziness, and itching

Local adverse events on ear related to device POD 4Post-operative Day 4

Recorded as yes/no for adverse events related to the device such as pain or skin irritation

Self-Reported Oral Opioid Use POD 5Post-Operative Day 5

Collected through the subject diary and recorded as total dosage (mg) taken

Adverse events related to opioid POD 6Post-Operative Day 6

Recorded as yes/no for adverse events related to opioids like nausea, vomiting, dizziness, and itching

Trial Locations

Locations (1)

UPMC Outpatient Center

🇺🇸

West Mifflin, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath